Onyango Calleb George, Ogonda Lilian, Guyah Bernard, Shiluli Clement, Ganda Gregory, Orang'o Omenge Elkanah, Patel Kirtika
Department of Biomedical Sciences and Technology, Maseno University, P.O Box Private Bag, Maseno, Kenya.
Department of Clinical Services, Division of Gynecology / Oncology, Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH), P.O Box 849, Kisumu, Kenya.
Infect Agent Cancer. 2020 Nov 16;15(1):68. doi: 10.1186/s13027-020-00335-2.
Cervical cancer screening is slowly transitioning from Pappanicolaou cytologic screening to primary Visual Inspection with Acetic Acid (VIA) or HPV testing as an effort to enhance early detection and treatment. However, an effective triage tests needed to decide who among the VIA or HPV positive women should receive further diagnostic evaluation to avoid unnecessary colposcopy referrals is still lacking. Evidence from experimental studies have shown potential usefulness of Squamous Cell Carcinoma Antigen (SCC Ag), Macrophage Colony Stimulating Factor (M-CSF), Vascular Endothelial Growth Factor (VEGF), MicroRNA, p16INKa / ki-67, HPV E6/E7/mRNA, and DNA methylation biomarkers in detecting premalignant cervical neoplasia. Given the variation in performance, and scanty review studies in this field, this systematic review described the diagnostic performance of some selected assays to detect high-grade cervical intraepithelial neoplasia (CIN2+) with histology as gold standard.
We systematically searched articles published in English between 2012 and 2020 using key words from PubMed/Medline and SCOPUS with two reviewers assessing study eligibility, and risk of bias. We performed a descriptive presentation of the performance of each of the selected assays for the detection of CIN2 + .
Out of 298 citations retrieved, 58 articles were included. Participants with cervical histology yielded CIN2+ proportion range of 13.7-88.4%. The diagnostic performance of the assays to detect CIN2+ was; 1) SCC-Ag: range sensitivity of 78.6-81.2%, specificity 74-100%. 2) M-CSF: sensitivity of 68-87.7%, specificity 64.7-94% 3) VEGF: sensitivity of 56-83.5%, specificity 74.6-96%. 4) MicroRNA: sensitivity of 52.9-67.3%, specificity 76.4-94.4%. 5) p16INKa / ki-67: sensitivity of 50-100%, specificity 39-90.4%. 6) HPV E6/E7/mRNA: sensitivity of 65-100%, specificity 42.7-90.2%, and 7) DNA methylation: sensitivity of 59.7-92.9%, specificity 67-98%.
Overall, the reported test performance and the receiving operating characteristics curves implies that implementation of p16ink4a/ki-67 assay as a triage for HPV positive women to be used at one visit with subsequent cryotherapy treatment is feasible. For the rest of assays, more robust clinical translation studies with larger consecutive cohorts of women participants is recommended.
宫颈癌筛查正逐步从巴氏细胞学筛查转向以醋酸肉眼观察法(VIA)或人乳头瘤病毒(HPV)检测为主,旨在加强早期检测与治疗。然而,目前仍缺乏一种有效的分流检测方法,用以确定VIA或HPV检测呈阳性的女性中哪些需要接受进一步的诊断评估,以避免不必要的阴道镜检查转诊。实验研究证据表明,鳞状细胞癌抗原(SCC Ag)、巨噬细胞集落刺激因子(M-CSF)、血管内皮生长因子(VEGF)、微小RNA、p16INKa / ki-67、HPV E6/E7/mRNA以及DNA甲基化生物标志物在检测宫颈上皮内瘤变方面具有潜在作用。鉴于这些检测方法的性能存在差异,且该领域的综述研究较少,本系统综述以组织学为金标准,描述了一些选定检测方法在检测高级别宫颈上皮内瘤变(CIN2+)方面的诊断性能。
我们使用来自PubMed/Medline和SCOPUS的关键词,系统检索了2012年至2020年间发表的英文文章,由两名评审员评估研究的合格性和偏倚风险。我们对每种选定检测方法检测CIN2+的性能进行了描述性呈现。
在检索到的298篇文献中,纳入了58篇文章。宫颈组织学检查的参与者中CIN2+的比例范围为13.7 - 88.4%。各检测方法检测CIN2+的诊断性能如下:1)SCC-Ag:敏感性范围为78.6 - 81.2%,特异性为74 - 100%。2)M-CSF:敏感性为68 - 87.7%,特异性为64.7 - 94%。3)VEGF:敏感性为56 - 83.5%,特异性为74.6 - 96%。4)微小RNA:敏感性为52.9 - 67.3%,特异性为76.4 - 94.4%。5)p16INKa / ki-67:敏感性为50 - 100%,特异性为39 - 90.4%。6)HPV E6/E7/mRNA:敏感性为65 - 100%,特异性为42.7 - 90.2%,以及7)DNA甲基化:敏感性为59.7 - 92.9%,特异性为67 - 98%。
总体而言,报告的检测性能和接受操作特征曲线表明,将p16ink4a/ki-67检测作为HPV阳性女性的分流检测方法,在一次就诊时使用并随后进行冷冻治疗是可行的。对于其他检测方法,建议开展更有力的临床转化研究,纳入更多连续的女性参与者队列。